Table 2.
Demographic and hormonal features of two groups of PCOS patients
| Characteristic | Treatment group (n = 20) | Control group (n = 20) | P value |
|---|---|---|---|
| Age (y) | 30.60 ± 4.98 | 30.45 ± 3.98 | 0.917 |
| BMI (kg/m2) | 28.91 ± 4.52 | 27.72 ± 5.47 | 0.458 |
| E2 (pg/mL) | 85.79 ± 46.76 | 80.12 ± 38.45 | 0.678 |
| P (ng/mL) | 1.26 ± 0.86 | 1.27 ± 0.87 | 0.978 |
| PRL (ng/mL) | 11.72 ± 6.31 | 12.14 ± 5.78 | 0.828 |
| LH (mU/mL) | 16.01 ± 7.47 | 14.06 ± 7.91 | 0.430 |
| FSH (mU/mL) | 4.79 ± 1.97 | 4.69 ± 1.44 | 0.857 |
| AMH | 12.28 ± 6.30 | 12.78 ± 6.29 | 0.800 |
| TSH | 2.18 ± 1.04 | 2.04 ± 0.98 | 0.658 |
Values are presented as mean ± SD. Treatment group received AST; control group received placebo. No statistically significant differences were found between the treatment group and the control group. BMI body mass index, E2 estradiol, P progesterone, PRL prolactin, LH luteinizing hormone, FSH follicle-stimulating hormone, AMH anti-Müllerian hormone, TSH thyroid-stimulating hormone